The US Food and Drug Administration's (FDA) approval of Dysport, a product manufactured by Paris-based Ipsen, has opened up a new era of competition in the US toxin market. This competition has been raging in Europe for years. It is important to note that if you experience any adverse effects after using Dysport, you should contact your doctor or seek medical help immediately. On November 18, the launch event of Dysport in China will bring together more than 400 CEOs, COOs and healthcare professionals (HCPs) from the most prominent companies in the aesthetic business.
The event will feature speakers such as Prof. Based on long-term manufacturing data, the formulation of Dysport has been shown to have a high degree of consistency in both long-term protein loading and biochemical and functional characteristics (such as endopeptidase activity). Bonta-ABO's Dysport formulation has a constant batch-to-batch toxin protein loading per vial of product (the amount of foreign protein per vial) with an average toxin protein content of 4.35 ng per vial of 50 units of 500 LD, based on data from multiple bulk batches of toxins from Dysport and clinical products in the entire manufacturing history. Since its introduction in 1991, Dysport has been developed for use with a variety of indications in the therapeutic areas of neurology, rehabilitation medicine, ophthalmology and dermatology, including cervical dystonia, adult and pediatric spasticity, blepharospasm and hemifacial spasm.
The day after the FDA approved Dysport as a new drug, it became the first true challenger to Botox in the United States. Dysport's production steps include a proprietary exclusive purification process using column chromatography and a unique and exclusive finishing process. This results in consistent and unique product characteristics. Studies have confirmed that Dysport has a high degree of long-term batch-to-batch consistency for a variety of specific properties, including specific potency, protein composition, toxin complex charge density properties, and endopeptidase activity.
The second step is the formulation, filling and freeze-drying of the final dosage form, the drug Dysport (DP). This formulation has been successfully used for nearly 20 years in Europe and other countries under the trade name Dysport (Clostridium botulinum type A toxin and hemagglutinin complex; Ipsen Biopharm, Wrexham, UK).
